Compare USAC & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USAC | XENE |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.2B |
| IPO Year | 2011 | 2014 |
| Metric | USAC | XENE |
|---|---|---|
| Price | $28.37 | $55.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $26.67 | ★ $67.17 |
| AVG Volume (30 Days) | 182.0K | ★ 1.5M |
| Earning Date | 05-20-2026 | 05-28-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $698,365,000.00 | $311,000.00 |
| Revenue This Year | $33.55 | N/A |
| Revenue Next Year | $6.83 | $2,823.63 |
| P/E Ratio | $31.25 | ★ N/A |
| Revenue Growth | ★ 19.51 | N/A |
| 52 Week Low | $21.59 | $26.74 |
| 52 Week High | $28.52 | $62.91 |
| Indicator | USAC | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 64.21 |
| Support Level | $22.62 | $38.36 |
| Resistance Level | N/A | $62.91 |
| Average True Range (ATR) | 0.73 | 2.50 |
| MACD | -0.02 | 0.94 |
| Stochastic Oscillator | 75.56 | 66.09 |
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.